Frazier Life Sciences Management, L.P.
Q3 2025 13F-HR Holdings
Net value change ($000)
+836,659
(33.5%)
New positions
4
Sold out positions
6
Turnover %
4.1%
Sector allocation + QoQ delta (equities-only)
Snapshot: Change Analysis
Compared to Q2 2025
Methodology:
sector metrics are equities-only;
instrument mix chart is ex-options;
options exposure is shown separately.
Why this matters.
Top Adds (Value $000, Stocks/ETFs)
| NAMS | 174,250 | 57.9% |
| MIRM | 152,346 | 44.1% |
| MAZE | 62,389 | 111.3% |
| MBX | 48,117 | 70.5% |
| ARQT | 47,694 | 34.5% |
| VRNA | 41,047 | 12.8% |
| TRVI | 37,755 | 67.3% |
| BBIO | 35,629 | 21.7% |
| ABVX | 32,118 | NEW |
| CYTK | 30,611 | 167.0% |
Top Reduces (Value $000, Stocks/ETFs)
| HilleVax, Inc. | -21,128 | -100.0% |
| CGON | -20,020 | -100.0% |
| COGT | -12,454 | -100.0% |
| ORIC | -10,813 | -100.0% |
| ALKERMES PLC | -7,610 | -26.6% |
| ORKA | -6,539 | -100.0% |
| EOLS | -6,279 | -28.0% |
| RARE | -6,178 | -17.3% |
| MREO | -6,136 | -24.0% |
| JBIO | -5,506 | -31.1% |
Instrument mix + QoQ Δ (ex-options)
How this table is calculated:
SEC
VALUE ($000) is used as reported.
For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received.
Column % is bucket-based:
non-options share is calculated inside non-option total, options share is calculated inside options total.
Details.
Filter:
Instrument:
| Issuer Name | Ticker | Sector | Industry | Class | History | Value ($000) | % | Shares | Shares Δ | Shares Δ% | Value Δ ($000) | Value Δ% | Principal | Option Type |
|---|